Communiqués Healios K.K.

Actions

4593

JP3835100003

Recherche biotechnologique et médicale

Marché Fermé - Japan Exchange 08:30:00 17/09/2026			Varia. 5j.	Varia. 1 janv.
297,00 ^JPY	+3,12%		+3,12%	+8,39%

27/07	Healios annonce la sélection du procédé de fabrication commerciale d'Akt-01/Hlcn061 pour le projet AMED	CI
08/04	La Bourse de Tokyo bondit, l'accord de cessez-le-feu entre les Etats-Unis et l'Iran apaise les craintes géopolitiques	MT

Communiqués

14/05	HEALIOS K.K. to Present at Jefferies Global Healthcare Conference	AQ
11/11	Healios K.K. to Present at Jefferies Global Healthcare Conference	AQ
21/10/25	Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference	AQ
28/05/25	Healios K.K. to Present at the 2025 Jefferies Global Healthcare Conference	AQ
10/08/22	Healios K K : TREASURE study results to be presented at the 14th World Stroke Congress	PU
12/07/22	Healios eNK Cells: Regenerative Medicine Product Quality Consultation with the PMDA for Planned Clinical Trials	PU
12/07/22	Healios K K : Exercise of Exclusive Option for a License Agreement with STEMAXON for the Development of UDC-Derived Photoreceptor Cells	PU
03/06/22	Healios’ eNK Cells: Joint Research with Hyogo Medical University for Mesothelioma	PU
06/04/22	Healios K K : Business Briefing for Institutional Investors	PU
04/04/22	Healios K K : Progress Update in Relation to Application for Approval for HLCM051 for ARDS	PU
04/04/22	Healios K K : Completion of 365 Days Post-Administration Follow Up for TREASURE Study for Patients with Ischemic Stroke	PU
01/04/22	Healios K K : Joint Research with the Division of Regenerative Medicine, the Institute of Medical Science for Developing a Mass Production Method of UDC Liver Buds	PU
24/03/22	Healios K K : License Agreement with CellFiber Co., Ltd.	PU
24/02/22	Healios K K : Notice Concerning Reduction of Capital Stock and Capital Reserves and Appropriation of Surplus	PU
24/02/22	Healios K K : Notice of the Partial Amendments to Articles of Incorporation	PU
24/02/22	Healios K K : Notice of the Nomination of Candidates for the HEALIOS K.K. Board of Directors	PU
31/01/22	Healios K K : Announcement of Change in Management	PU
21/12/21	Healios K K : ’ Gene-Edited NK Cells：Joint Research with Hiroshima University for Hepatocellular Carcinoma	PU
01/12/21	Healios K K : Data from Athersys’ clinical trial evaluating MultiStem cell therapy for ARDS published in Intensive Care Medicine	PU
12/11/21	FY2021 Q3 Financial Results	PU
08/11/21	The anti-tumor effect of Healios' gene edited iPSC-derived NK cells in a lung cancer cell line	PU
15/09/21	Healios K K : Announcement of Determination of the Issue Price and Other Matters for the Issuance of New Shares through an International Offering	PU
15/09/21	Healios K K : Announcement of Issuance of New Shares through an International Offering	PU
02/09/21	Healios K K : Successful differentiation of Healios UDCs into pancreatic β-cells in our joint research with the National Center for Global Health and Medicine	PU
10/08/21	Healios K K : Full Enrolment of TREASURE Study for Patients with Ischemic Stroke	PU